Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hypomethylating Therapy for Post-HCT Relapse

Biol Blood Marrow Transplant; ePub 2016 Oct 24; Woo, et al

Publish date:: November 16, 2016

Using hypomethylating therapy for post-HCT relapse appears to be valuable and suggests that pre-HCT therapy may affect the likelihood of response, according to a prospective trial involving 39 individuals.

Participants had myelodysplastic syndrome or acute myeloid leukemia. Investigators looked at relapse at 6 months after treatment with 5-azacitidine, 75 mg/m2/day for 7 days, given every 28 days. Among the results:

There were 3 complete remissions and 9 partial remissions.
3 additional patients had stable disease according to International Working Group criteria.
In multivariate analysis, only the type of induction chemotherapy given before HCT was significantly linked with post-HCT response to 5-azacitidine and overall survival.

Citation:

Woo J, Deeg J, Storer B, et al. Factors determining responses to azacitidine in patients with MDS and AML with early post-transplant relapse: A prospective trial. [Published online ahead of print October 24, 2016]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2016.10.016.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,